Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A real-world study to determine toxicity in patients with acute lymphoblastic leukemia who received inotuzumab ozogamicin prior to HSCT from a registry -Center for International Blood and Marrow Transplant Research [CIBMTR])

Next Previous
X
Search
Trial Profile

A real-world study to determine toxicity in patients with acute lymphoblastic leukemia who received inotuzumab ozogamicin prior to HSCT from a registry -Center for International Blood and Marrow Transplant Research [CIBMTR])

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inotuzumab ozogamicin (Primary)
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 13 Dec 2022 Interim Results (n=196,at 4 years from August 18, 2017, to August 17, 2021) assessing post HSCT outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 30 Jul 2021 New trial record
    • 17 Jun 2021 Interim results (at three years) presented at the 26th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top